- Combined injectable contraceptive
-
Combined Injectable Contraceptive Background Birth control type Hormonal First use about 1980 Failure rates (first year) Perfect use 0-0.2[1]% Typical use ? Usage Duration effect 1 month User reminders ? Advantages and disadvantages STD protection No Benefits Especially good if poor pill compliance. Combined injectable contraceptive (CIC) monthly injection of progesterone and estradiol taken to inhibit fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle and Cyclo-Provera.
DMPA is a different injectable contraceptive, containing just a progestin, given every three months.
Contents
History
- October 5, 2000, Pharmacia received FDA approval for Lunelle Monthly Contraceptive Injection.[1]
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-Provera (DMPA)).
- October 2003, Lunelle was discontinued in the U.S.
Use and packaging
Administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh.[1] Ideally administered every 28 to 30 days, though demonstrated to be effective up to 33 days.[1]
Side-effects
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.[1]
Formulations
- Lunelle contains medroxyprogesterone acetate (MPA) 25 mg plus estradiol cypionate (E2C) 5 mg.[1]
- Cyclofem contains depomedroxy-progesterone acetate (DMPA) 25 mg and estradiol cypionate 5 mg.
- Mesigyna contains norethisterone enanthate (NET EN) 50 mg and estradiol valerate 5 mg.
- Deladroxate contains dihydroxy-progesterone acetophenide 150 mg and estradiol enanthate 10 mg.
See also
Footnotes
- ^ a b c d e f "FDA Approves Combined Monthly Injectable Contraceptive" ([dead link]). Contraception Report 12 (3). 2001. http://www.contraceptiononline.org/contrareport/article01.cfm?art=176.
Birth control methods (G02B, G03A) Comparison Behavioral Avoiding vaginal intercourse: Abstinence • Anal sex • Masturbation • Non-penetrative sex • Oral sex
Including vaginal intercourse: Breastfeeding infertility (LAM) • Calendar-based methods (rhythm, etc.) • Fertility awareness • WithdrawalBarrier or
spermicidalHormonal
(formulations)Progestogen-onlyAnti-estrogen Ormeloxifene (Centchroman)Post-intercourse Emergency contraception (pills or copper IUD) (Yuzpe regimen, Ulipristal acetate)Intrauterine device Abortion Sterilization Program for Appropriate Technology in Health (PATH) Key people Christopher Elias, CEOProjects Products This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.